Transplant News and Research

RSS

Advance team of molecules produced by primary tumor is responsible for lung cancer metastasis

Cancer metastasis requires tumor cells to acquire properties that allow them to escape from the primary tumor site, travel to a distant place in the body, and form secondary tumors. But first, an advance team of molecules produced by the primary tumor sets off a series of events that create a network of nurturing blood vessels for arriving primary tumor cells to set up shop.

20 Aug 2013

New type of cancer immunotherapy harnesses body's immune system to attack tumors

By carefully adjusting the function of crucial immune cells, scientists may have developed a completely new type of cancer immunotherapy—harnessing the body's immune system to attack tumors. To accomplish this, they had to thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responses.

19 Aug 2013

Study shows lymph node location influences maturation process of cells they contain

Based on their observations, the scientists deduced that lymph node location influences the maturation process of the cells they contain. "The cells retained their original skills for weeks following the transplant," says Dr. Sascha Cording, one of the study's first authors. "You might say lymph nodes have something like a location-specific memory."

17 Aug 2013

DLBCLs resistant to chemotherapy can be reprogrammed to respond using azacitidine

A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

17 Aug 2013

Viewpoints: George will assails 'illegal' delay of employer mandate; Cohn reminds conservatives that subsidies will be important

Barack Obama's increasingly grandiose claims for presidential power are inversely proportional to his shriveling presidency. Desperation fuels arrogance as, barely 200 days into the 1,462 days of his second term, his pantry of excuses for failure is bare, his domestic agenda is nonexistent and his foreign policy of empty rhetorical deadlines and redlines is floundering. And at last week's news conference he offered inconvenience as a justification for illegality.

16 Aug 2013

Six months of intravenous fish oil reverses pediatric intestinal failure associated liver disease

Children who suffer from intestinal failure, most often caused by a shortened or dysfunctional bowel, are unable to consume food orally. Instead, a nutritional cocktail of sugar, protein and fat made from soybean oil is injected through a small tube in their vein.

16 Aug 2013

Johns Hopkins expert says crucial ethics should be considered in HIV cure research

A cure for HIV infection - the International AIDS Society meeting in Kuala Lumpur in early July offered new hope of the possibility, after researchers announced that two "Boston patients" had shown no resurgence of the virus after receiving a bone marrow transplant and ceasing their antiretroviral therapy (ART).

14 Aug 2013

Proton therapy provides organ-sparing treatment option for children with neuroblastoma

Proton therapy, using high-energy subatomic particles, may offer a precise, organ-sparing treatment option for children with high-risk forms of neuroblastoma. For patients in a new study of advanced radiation treatment, proton therapy spared the liver and kidneys from unwanted radiation, while zeroing in on its target.

14 Aug 2013

Virus-derived particles developed to kill human blood cancer cells, eradicate disease in mice

Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects. The study is published in Blood Cancer Journal by co-senior authors Drs. David Conrad and John Bell of the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa).

14 Aug 2013

Saint Luke's Heart Institute seeks talented individuals for postdoctoral cardiovascular research

Saint Luke's Mid America Heart Institute—one of the leading outcomes research centers in the nation—is seeking highly motivated, talented individuals for its two-year postdoctoral training program in cardiovascular outcomes research.

12 Aug 2013

ProMedica and Cleveland Clinic collaborate to develop health system affiliation

ProMedica and Cleveland Clinic have signed a Memorandum of Understanding to develop a health system affiliation that will better position both organizations to anticipate and proactively respond to the evolving healthcare landscape.

9 Aug 2013

One-third of patients with heart pumps develop infection at abdominal power connection site

Cardiac surgeons and cardiologists at the University of Maryland Heart Center are part of a multi-center clinical trial evaluating the efficacy of powering heart pumps through a skull-based connector behind the ear. Typically, these devices for patients with severe heart failure are energized through an electrical cord connected at an abdominal site, where potentially deadly infections can develop.

8 Aug 2013

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.

8 Aug 2013

New bio-artificial "encapsulife" pancreas points to cure for diabetes

The Squash Diabetes Campaign, launched by the Georgetown University Women's Squash Team* in December 2012 and sponsored by New Generation Foundation, today announced a $125,000 grant provided by the Chicago-based Chauncey and Marion D. McCormick Family Foundation.

8 Aug 2013

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial.

8 Aug 2013

Nearly 59% of liver transplant patients experience metabolic syndrome

Nearly 59 percent of liver transplant patients experience metabolic syndrome, which increases the risk of heart disease, stroke and diabetes, according to a study lead by liver specialist Eric R. Kallwitz, MD, of Loyola University Medical Center.

8 Aug 2013

Exercise could reduce metabolic disease complications in patients post-transplantation

New research reveals that metabolic syndrome—risk factors that can lead to heart disease and/or stroke—is common in liver transplant recipients, with rates highest at one year following the procedure.

7 Aug 2013

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Patients with advanced chronic lymphocytic leukemia often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the transplanted immune cells may also harm normal tissues, causing graft-versus-host disease.

7 Aug 2013

Exercise could help reduce metabolic syndrome problems in liver transplant recipients

New research reveals that metabolic syndrome-risk factors that can lead to heart disease and/or stroke-is common in liver transplant recipients, with rates highest at one year following the procedure.

7 Aug 2013

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that most often affects older adults. CLL responds to bone marrow stem cell transplantation (allo-HSCT); however, the rate of relapse for CLL remains relatively high.

6 Aug 2013

Transplant News and Research

Advance team of molecules produced by primary tumor is responsible for lung cancer metastasis

New type of cancer immunotherapy harnesses body's immune system to attack tumors

Study shows lymph node location influences maturation process of cells they contain

DLBCLs resistant to chemotherapy can be reprogrammed to respond using azacitidine

Viewpoints: George will assails 'illegal' delay of employer mandate; Cohn reminds conservatives that subsidies will be important

Six months of intravenous fish oil reverses pediatric intestinal failure associated liver disease

Johns Hopkins expert says crucial ethics should be considered in HIV cure research

Proton therapy provides organ-sparing treatment option for children with neuroblastoma

Virus-derived particles developed to kill human blood cancer cells, eradicate disease in mice

Saint Luke's Heart Institute seeks talented individuals for postdoctoral cardiovascular research

ProMedica and Cleveland Clinic collaborate to develop health system affiliation

One-third of patients with heart pumps develop infection at abdominal power connection site

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

New bio-artificial "encapsulife" pancreas points to cure for diabetes

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Nearly 59% of liver transplant patients experience metabolic syndrome

Exercise could reduce metabolic disease complications in patients post-transplantation

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Exercise could help reduce metabolic syndrome problems in liver transplant recipients

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News